Compare Novavax Inc (NVAX) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs PulteGroup, Inc. — how do they compare? Novavax Inc trades at $7.94 (market cap $1.30B), while PulteGroup, Inc. trades at $132.77 (market cap $24.77B). The key difference: PulteGroup, Inc. is far larger — about 19.1× Novavax Inc's market cap, and PulteGroup, Inc. pays a 0.8% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | PHM | |
|---|---|---|
Market Cap | $1.30B | $24.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $142.56 |
52-Week Low | $6.22 | $110.11 |
Enterprise Value | $879.40M | $25.19B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
PulteGroup (PHM) trades at $132.90, up 2.59% today, with a bullish technical signal and support near $131. The stock shows solid fundamentals with a P/E of 13.58 and net income margin of 11.62%, though recent quarters saw mixed earnings results. The company expanded into Northwest Florida and reported a Q2 2026 EPS beat, while cash flow trends remain positive.
Outlook is cautiously optimistic with a consensus price target of $137.20 offering modest upside. Risks include housing market pressure and margin declines, but strong institutional interest and a moderate buy rating suggest resilience. The stock presents a value opportunity amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
